Hu Xinhang, Hu Qikang, He Yu, Yi Xuyang, Wu Zeyu, Hu Huali, Ouyang Yifan, Yu Fenglei, Peng Muyun
Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China.
Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital of Central South University, Changsha, China.
Clin Imaging. 2024 Mar;107:110070. doi: 10.1016/j.clinimag.2023.110070. Epub 2024 Jan 5.
Lung cancer remains the primary cause of cancer-related mortality globally. In the case of early-stage non-small cell lung cancer (NSCLC), surgical resection, such as lobectomy and sub-lobectomy, continues to be the established standard treatment. However, for patients with insufficient cardiopulmonary function and multiple comorbidities who are unable to undergo surgical resection, nonoperative local therapies, including radiotherapy and thermal ablation, are preferred. In recent years, microwave ablation (MWA) has gained popularity for treating early-stage NSCLC due to its high heating efficiency, good tissue conductance, and heat conduction capabilities. This review provides a comprehensive summary of the current efficacy and safety data regarding MWA for early-stage NSCLC and discusses the potential benefits of combining MWA with other therapies.
肺癌仍然是全球癌症相关死亡的主要原因。对于早期非小细胞肺癌（NSCLC），手术切除，如肺叶切除术和肺段切除术，仍然是既定的标准治疗方法。然而，对于心肺功能不足且有多种合并症而无法进行手术切除的患者，包括放疗和热消融在内的非手术局部治疗是首选。近年来，微波消融（MWA）因其加热效率高、组织传导性好和热传导能力强，在治疗早期NSCLC方面受到欢迎。本综述全面总结了目前关于MWA治疗早期NSCLC的疗效和安全性数据，并讨论了将MWA与其他疗法联合使用的潜在益处。
